Brief: Immunovia Q4 Operating Loss Widens To SEK 29.6 Million

Immunovia AB (publ)

14/02/2020 07:14

Feb 14 (Reuters) - Immunovia AB (publ)  IMMNOV.ST :
    * IMMUNOVIA FULL YEAR REPORT 2019
    * Q4 NET SALES SEK 45,000 VERSUS SEK 91,000 YEAR AGO
    * Q4 OPERATING LOSS SEK 29.6 MILLION VERSUS LOSS SEK 25.7
MILLION
YEAR AGO
    * WE REMAIN FOCUSED ON INTRODUCING OUR BLOOD-BASED TEST TO
MARKET
IN Q3 2020
    * WITH TWO MILESTONES REMAINING BEFORE COMMERCIALIZATION OF
IMMRAY
TECHNOLOGY IN Q3 2020, WE ARE INTENSIFYING FINAL LAUNCH
PREPARATIONS
    * WE WILL MARKET IMMRAY PANCAN-D FIRST IN USA AND THEN IN
EUROPE
    * WE CONTINUE TO INCREASE SPEED OF OUR COMMERCIALIZATION
EFFORTS
FOR A SUCCESSFUL LAUNCH OF IMMRAY PANCAN-D

Source text for Eikon:  ID:nWkr3khC6C 
Further company coverage:  IMMNOV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))